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Abstract
Background: Castleman's disease (CD), a rare condition of uncertain etiology, involves a massive
proliferation of lymphoid tissues and typically presents as mediastinal masses. We describe a patient
with CD who presented with diffuse adenopathy involving the inguinal, paratracheal,
retroperitoneal, axillary, and pelvic regions.
Case presentation: Case report describing presentation, work-up, management and clinical
course of a patient with Castleman's disease in the setting of a county hospital in metropolitan area.
Patient was treated with chemotherapeutic agents.
Conclusions: To our knowledge, this represents the first case of CD involving an HIV-positive
patient with a negative Human Herpes Virus (HHV-8) viral panel. Because patients with similar
clinical histories are at high risk for the development of non-Hodgkin's lymphoma and Kaposi
sarcoma, regular medical surveillance is recommended.
Background
Castleman's disease (CD) involves a massive non-malig-
nant proliferation of lymphoid tissues and typically
presents as mediastinal masses. This uncommon condi-
tion was initially described among a small series of
patients in 1956. [1] Castleman's affects patients of vary-
ing ages and cases have been reported from adolesence
into the seventh decade. [2]
Most cases of Castleman's Disease represent either the
hyaline vascular variant (80–90% of cases) or the plasma
cell variant (10–20%); a small percentage present with a
mixed histologic appearance. [3] Patients with the hyla-
line vascular form of CD may exhibit no symptoms or
only lymphadenopathy while persons with the plasma
cell variant typically present with fever, weight loss, rash
and anemia. Multifocal or Multicentric Castleman's Dis-
ease (MCD), is a systemic form of the plasma cell variant
with patients exhibiting generalized peripheral lymphad-
enopathy, hepatosplenomegaly, frequent fevers, and
night sweats. [4] Treatment can range from curative sur-
gery for the hyaline form of CD to the use of chemother-
apy for MCD.
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Case presentation
In 06/01, a white male in his fourth decade presented to
the emergency department of a metropolitan county hos-
pital with a 3-month history of an enlarging right inguinal
mass. He noted accompanying scrotal swelling, night
sweats, and groin pain, rated as 4/10 in severity, intermit-
tent in nature with radiation to the surrounding inguinal
area and right testicle.
This patient had been admitted to the same institution
one month earlier with the same complaints. At that time,
a fine needle biopsy of the right inguinal node was done
and the patient was discharged with instructions for med-
ical follow-up. Pain medications were prescribed for
symptom control. Before the date of the follow-up visit,
the patient returned to the emergency department with
the same complaints. The needle biopsy result was subse-
quently reported as "negative for malignant cells."
Past medical history was significant for infection with
Human Immunodeficiency Virus (HIV) and four episodes
of pneumocystis carinii pneumonia (most recent in
2000), consistent with a diagnosis of Autoimmune Defi-
ciency Syndrome (AIDS); (a subsequent CD4 count com-
pleted in July 2001 was 108/microliter). This patient also
reported bilateral hip pain, neuropathic foot pain bilater-
ally and gastroesophageal reflux disease. Past surgical his-
tory revealed repair of a right inguinal hernia as a child,
right inguinal fine needle biopsy 5/01, and repair of a left
undescended testis as a child. Medications at the time of
admission included: efavirenz 600 milligrams (mg) once
daily, stavudine 40 mg twice daily, lamivudine 150 mg
twice daily, sulfamethoxazole/trimethoprim (800 mg/
160 mg) once daily, lansoprazole 15 mg daily, nortryptyl-
ine 75 mg daily.
A review of systems was significant for a weight loss of five
pounds over the past month and the chronic hip pain
reportedly previously diagnosed as osteoarthritis.
At presentation, the oral temperature was 99.1 degrees
Fahrenheit and a heart rate of 108; vital signs were other-
wise unremarkable. The patient was noted to be con-
scious, alert and oriented but somewhat agitated; beads of
sweat were noted on his forehead. Physical examination
was significant for mild pallor, left axillary lymphadenop-
athy, diffuse abdominal tenderness, mild hepat-
osplenomegaly and 2+ pitting edema involving the
proximal right lower extremity. This edema involved the
right inguinal region and extended inferiorly to the upper
thigh; right thigh diameter was noticeably larger than the
left (objective measurement not recorded). Genital exam-
ination revealed a circumcised, thickened, doughy penis
and an enlarged right non-erythematous testicle with mild
tenderness to palpation/manipulation. The right inguinal
area was swollen, firm and tender with massive adenopa-
thy measuring 12 centimeters (cm) by 8 cm; no discharge
or warmth to touch was noted. The left groin area revealed
a well-healed inguinal scar consistent with prior surgery
and non-tender adenopathy recorded as 4 cm by 2 cm
without erythema, warmth, or discharge.
Initial laboratory testing included a complete blood count
with differential, chemistry panel, coagulation panel, uri-
nalysis, and computerized tomography (CT) scans of the
abdomen and pelvis. Blood tests were unremarkable
except for mild anemia with hemoglobin of 10.2 grams/
deciliter (g/dl). The CT scan revealed extensive retroperi-
toneal, pelvic, and bilateral inguinal adenopathy [figure
1].
Following an initial assessment in the emergency depart-
ment, this patient was admitted for further work-up and
pain control. Differential diagnoses were focused on
infectious and malignant etiologies [table 1].
Upon admission, additional laboratory studies were
ordered including repeat complete blood count with dif-
ferential, liver profile, Erythrocyte Sedimentation Rate
(ESR), protein electrophoresis, and serum immunoelec-
trophoresis to rule out multiple myeloma, given the
chronic hip pain.
CT scan of the chest showed an enlarged right paratracheal
lymph node. Radiographs of right hip revealed mixed
sclerotic and lytic lesions of the acetabulum and femur.
Bone scan showed increased uptake in right femoral head,
trochanter and proximal shaft of femur. The differential
diagnosis at this point included lymphoma, multiple
myeloma, and HIV adenopathy. Surgical and infectious
disease consultations were requested.
The infectious disease service noted this patient's immu-
nocompromised status and the possibility of an ineffec-
tive febrile response. Accordingly, the possibility of an
infectious etiology was expanded to include infectious
adenitis, disseminated mycobacterium avium intercellulare
(MAC) infection, disseminated tuberculosis, cryptococco-
sis, histoplasmosis and rhodococcus equi (Nocardia restricta).
Histoplasmosis was unlikely as there was no reported travel
to histoplasmosis endemic regions. Additional studies
were performed: hepatitis profile to rule out hepatitis
infection and a viral panel (Human Herpes Virus [HHV]-
8, Human T-cell Lymphotrophic Virus [HTLV]-1 & HTLV-
11, and Epstein Barr Virus [HBV]), since viral infections
have been associated with certain malignancies in HIV-
positive patients.
Open biopsy and fine needle re-biopsy of the right
inguinal lymph nodes were completed by the surgicalBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/20
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service. The specimens from these biopsies were sent to
pathology for histologic review, bacterial culture, fungal
culture, viral culture, and acid-fast bacilli staining. Flow
cytometry and repeat CD4 count and HIV RNA load was
performed to assess current immune status and to rule out
lymphoma.
The repeat complete blood count revealed normal lym-
phocyte (3,100 /mm3) and absolute neutrophil counts
Pre-treatment and post-treatment CT Scans showing diffusely enlarged retroperitoneal adenopathy (see arrows) and subse- quent disappearance following chemotherapy Figure 1
Pre-treatment and post-treatment CT Scans showing diffusely enlarged retroperitoneal adenopathy (see arrows) and subse-
quent disappearance following chemotherapy.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/20
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(9,600/mm3) and stable mild anemia (hemoglobin 10.8
g/dl). ESR was 125 mm/hour. Negative Rapid Plasmin
Reagin (RPR) testing served to rule out syphilis. Two sets
of blood cultures were negative for bacterial growth. The
viral, fungal and bacterial studies, as well as acid-fast test-
ing on the biopsied lymph node material were all nega-
tive. Flow cytometry was negative. Protein electrophoresis
showed high alpha 2 levels, a faint Immunoglobulin G
kappa band, and low albumin, essentially ruling out mul-
tiple myeloma. The hepatitis panel was negative. A liver
function panel revealed an alanine aminotransaminase
level of 194 units/liter, alkaline phosphatase of 253 units/
liter and lactase dehydrogenase of 726 IU/liter, essentially
unchanged from values noted at time of admission.
An ultrasensitive HIV RNA assay was undetectable and the
CD4 count, which was initially 27/microliter, became
undetectable during the hospital course. The patient's low
CD4 was determined to be secondary to abnormal lym-
phocyte processing and cell turnover resulting from his
current disease process, rather than failure of the highly
active anti-retroviral therapy (HAART) and patient was
continued on HAART by the infectious disease consultant.
Histologic evaluation revealed atrophic lymphoid folli-
cles with small germinal centers and cellular reticular
stroma with increased populations of plasma cells (see
Figure 2 and Figure 3). A review of these specimens by
pathology staff at a nearby comprehensive cancer center
noted "florid HIV-associated plasma cell hyperplasia" and
suggested the possibility of Castleman's Disease since this
disorder is a plasma cell variant associated with inter-
leukin 6 (IL-6) syndrome. Immunohistochemical stains
demonstrated both kappa and lambda positive cells,
which are non-specific pathologic findings in Castleman's
disease as well as other malignant conditions.
The patient's clinical presentation of non-infectious lym-
phadenopathy (all cultures negative), in combination
with the absence of typical pathognomic features support-
ing a diagnosis of Castleman's Disease, necessitated a
comprehensive review of published literature by the in-
patient medical team. Following completion of this
review, along with input from the infectious disease
consultant, it was determined that this patient's diagnosis
was a multicentric type of Castleman's Disease.
Accordingly the patient was started on a chemotherapy
regimen of doxorubicin, vincristine, cyclophosphamide
and prednisone by the hematology/oncology service. The
patient appeared to tolerate this well, achieving some res-
olution of edema as well as adequate pain control.
This patient was discharged to home on day 3 following
the first course of chemotherapy, with instructions for fur-
ther out-patient follow-up with the oncologist. This
patient received a total of six courses of chemotherapy and
has remained in remission approximately 18 months fol-
lowing diagnosis (see figure 1 for post-treatment CT
scans), although he continues to complain of hip pain.
Discussion
Castleman's Disease (CD) represents a distinct clinico-
pathological entity first described by Dr. Benjamin Castle-
man in 1956. [1] Castleman's report described a series of
13 patients with a condition characterized by localized
non-malignant mediastinal lymphadenopathy. Most sub-
sequent case series have described affected patients rang-
ing in age between the second and seventh decades. [2]
There are two pathological types of Castleman's Disease –
the hyaline vascular variant and plasma cell variant. The
hyaline vascular variant exhibits prominent proliferation
of small hyalinized follicles with marked interfollicular
Table 1: Initial and expanded differential diagnoses for male HIV(+) patient who presented with painful right inguinal adenopathy
Initial Differential Expanded Differential
Infectious:
-tuberculosis, atypical mycobacterium
-lymphogranuloma venereum
-cat scratch disease
-HIV adenopathy
-sebaceous cyst
-sporotrichosis
-other infections (e.g., sexually transmitted diseases)
Infectious:
-adenitis
-disseminated mycobacterium avium intercellulare
-disseminated tuberculosis
-cryptococcus
-histoplasmosis
-nocardia restricta
Malignant:
-Hodgkins' Disease
-non-Hodgkins' lymphoma
-AIDS-related lymphoma
-multiple myeloma
-testicular cancer
Malignant:
-angiosarcomaBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/20
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vascular proliferation, but while the plasma cell variant
exhibits hyperplastic germinal centers, sheets of plasma
cells in the interfollicular region, proliferation of blood
vessels, and persistent sinuses. It is postulated that 10 – 20
percent of all cases are of the plasma cell variant, with a
small percentage being of mixed histologic appearance.
[3] Multicentric Castleman's Disease (MCD) or multifocal
disease, is usually the plasma cell variant, and is a systemic
disease with generalized peripheral lymphadenopathy,
hepatosplenomegaly, frequent fevers, and night sweats.
[4]
The first case of MCD, which presented as generalized
lymphadenopathy with systemic manifestations of fever,
night sweats, weight loss and fatigue, was reported in
1978. [5] Castleman's typically presents in patients' ages
50 to 65 years, but for those who are HIV (+), it presents
at a younger age, as in the patient described in this report.
HIV seropositive individuals appear to be at an increased
risk for MCD, [5–7] and it can often arise concurrently
with Kaposi sarcoma (KS). It has been reported that
among HIV (+) patients with multicentric CD who are
infected with HHV-8, up to 70 percent will develop KS at
some time in their clinical course. [6–9] MCD commonly
results in a fatal outcome due to infectious complications,
multi-organ failure, and development of malignancies
such as lymphoma (Hodgkin's and non-Hodgkin's) or
Kaposi sarcoma. [7,9,10] In contrast, localized, Castle-
man's Disease, also referred to as unifocal or unicentric
disease (UCD), is typically an isolated benign lymphopro-
liferative disorder of young adults, is usually not associ-
ated with HHV-8 infection, and is generally curable with
surgical resection (with or without radiotherapy). [10–
12,3]
In some patients, multi-centric disease has been associ-
ated with both HIV infection and co-infection with
human herpesvirus-8 (HHV-8). HHV-8 is also known as
Kaposi sarcoma-associated virus, [5–7,14] and it is postu-
lated that HHV-8 produces interleukin 6 and is responsi-
ble for lymphoplasmacytic proliferation. [5–8,15]
Moreover, the presence of other human cytokines pro-
duced by HHV-8 could contribute to lymphoplasmacyto-
sis and to endothelial proliferation. [16] In one study,
HHV-8 sequences were found in lymph nodes in all 14
cases of HIV(+) MCD and in 7 of 17 cases of HIV(-) MCD,
as compared to 1 of 51 HIV(-) reactive lymph nodes and
3 of 17 HIV(+) reactive lymph nodes. [1] Other studies
have confirmed that HHV-8 appears to be universally
Plasma cell infiltrate in inguinal lymph node biopsy Figure 2
Plasma cell infiltrate in inguinal lymph node biopsy. Atrophic 
follicles (magnification 40×). Bottom.
plasma cell proliferation
asma cell proliferation
Plasma cells are identified by their eccentric, clock-face  nucleus and pale perinuclear cytoplasmic crescent. Figure 3
Plasma cells are identified by their eccentric, clock-face 
nucleus and pale perinuclear cytoplasmic crescent. Staining 
by hematoxylin-eosin stain (magnification 400×).BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/20
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found in HIV (+) MCD patients and in approximately 40
to 50 percent of MCD patients who are HIV (-) MCD. [1]
Interestingly, our patient was negative for HHV-8 virus,
based upon negative PCR and immunohistochemistry for
blood and lymph node biopsy specimens, which appears
to be the first report of an HIV (+) patient with MCD who
is negative for HHV-8 infection.
It has been suggested that expression of Castleman's Dis-
ease is partly due to IL-6 activity; HHV-8 is known to
encode a viral IL-6. One hypothesis for the origin of MCD
is that HHV-8 expresses viral IL-6, which induces vascular
endothelial growth factor (VEGF), which then induces
human IL-6 production by endothelial cells. [19] Use of
neutralizing antibodies against IL-6 and monoclonal anti-
body blocking the IL-6 receptor, have demonstrated clini-
cal efficacy, resulting in symptom resolution. [20,21] All
seven patients, in one study, treated with monoclonal
antibodies to IL-6 receptor had resolution of their clinical
symptoms, followed by improvement in their lymphade-
nopathy. [22] Once therapy was stopped, however, symp-
toms recurred. It is possible that the lymphoproliferation
noted in our patient was stimulated via other cytokine
pathways possibly associated with HIV infection or by an
as yet undiscovered mechanism.
After the exclusion of Hodgkin's disease, non-malignant
lymphoma, and an infectious etiology, multicentric Cas-
tleman's disease (MCD) remained the likely diagnosis in
this patient. In addition, the high ESR, in combination
with a constellation of relevant clinical signs and symp-
toms, such as extensive lymphoadenopathy, hepat-
osplenomegaly, night sweats and plasma cell hyperplasic,
negative laboratory work up and a history of HIV/AIDS,
further supported the diagnosis. The diagnosis was subse-
quently confirmed via histopathologic evaluation.
Another clinical observation is the association of MCD
with POEMS (polyneuropathy, organomegaly, endocrin-
opathy, monoclonal protein, and skin changes) syn-
drome. [23] Our patient demonstrated
hepatosplenomagaly, polyneuropathy, high alpha 2 pro-
tein and skin changes around the genitalia. Although only
four aspects of the POEMS syndrome were manifested in
our patient, this is similar to presentations reported in
other MCD cases. [3]
At present, there is no consensus as to the optimal man-
agement strategy for MCD. Successful treatment of MCD
has been achieved using chemotherapy, with or without
prednisone, given at the time of initial diagnosis. [5] The
chemotherapeutic agents used in the various case series
that have yielded remissions include doxorubicin, vincris-
tine, cyclophosphamide, melphalan and chlorambucil.
These have been used as single agents, together with ster-
oids or in combination (e.g., CHOP). Azathioprine and
bone marrow transplantation have also been attempted,
especially following failure of CHOP, but have yielded
mixed results. [3]
In a case series of seven patients, chemotherapy alone,
both as a single agent and in combination with corticos-
teroids, was used with mixed results: six of the patients
died of varied causes (lymphoma, Kaposi sarcoma (n = 3),
encephalitis and unknown cause); one patient treated
with meticorten survived but length of survival was not
stated. [24] Another series of 15 patients with MCD
treated with chemotherapy produced clinical responses in
14 of 15 patients (93 %); however, only 7 of 15 patients
(47%) were reported to be alive and 4 (27%) had no evi-
dence of disease. [3] No duration of response or survival
with chemotherapy was noted in that report.
Subsequent follow-up contact with both the patient and
attending oncologist approximately 18 months following
diagnosis, documented an excellent response to the chem-
otherapy regimen and no evidence of active disease; he
remains under active surveillance. It should be noted that
because of this medical history, this patient is considered
to be at high risk for the development of non-Hodgkin's
lymphoma and Kaposi sarcoma and regular medical fol-
low up is indicated.
Conclusion
Our patient represents the first report of an HIV/AIDS
patient with MCD found to be negative for HHV-8 infec-
tion. This case also illustrates additional unique clinical
features at time of presentation, including extensive aden-
opathy of multiple sites and various components of the
POEMS syndrome. This patient, and others with similar
clinical histories, is at high risk for the development of
non-Hodgkin's lymphoma and Kaposi sarcoma and on-
going medical follow up is necessary.
It is important to consider CD in the differential diagnosis
for patients presenting with extensive lymphadenopathy,
especially those with acquired immunodeficiency. The
clinical index of suspicion for CD or MCD is heightened
by the presence of other factors such as HIV infection/
AIDS, hypoalbuminemia, POEMS syndrome, hypergam-
maglobunemia, fever of unknown origin, and night
sweats.
Given the guarded prognosis for Castleman's disease, it is
prudent to pursue appropriate diagnostic work up for this
condition along with other differential diagnoses in order
to arrive at an accurate diagnosis and prescribe appropri-
ate therapy. Confirmation of the diagnosis should be
based upon the combination of medical history, clinical
findings, and histopathological evaluation.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/20
Page 7 of 7
(page number not for citation purposes)
Competing Interests
None declared.
Author Contributions
IS prepared an initial draft and coordinated revisions,
MCM participated in manuscript revisions and develop-
ment of the final manuscript and KT also provided revi-
sions to the text. IS and MCM conceived of this report.
Acknowledgements
We thank staff at the Erie County Medical Center for assistance in evalua-
tion of this patient. In particular, we acknowledge the contributions of 
Terry Makson, Ross Richer, Dr. Slate and Dr. Balos for administrative and 
technical support. Written consent was obtained from the patient for pub-
lication of this report.
References
1. Castleman B, Iverson I and Menendez VP: Localized mediastinal
lymph-node hyperplasia resembling thymoma. Cancer 1956,
9:822-830.
2. Herrada J, Cabanillas F, Rice L, Manning J and Pugh W: Clinical
behavior of localized and multicentric Castleman's disease.
Annals of Internal Medicine 1998, 128:657-662.
3. Keller AR and Hochholzer L: Hyaline-vascular and plasma-cell
types of giant lymph node hyperplasia of the mediastinum
and other locations. Cancer 1972, 29:670.
4. Peterson BA and Frizzera G: Multicentric Castleman's disease.
Semin Oncol 1993, 20(6):636-47.
5. Gaba AR, Stein RS, Sweet DL and Variakojis D: Multicentric giant
lymph node hyperplasia. Am J Clin Pathol 1978, 69:86-90.
6. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA,
Isaacson PG and Boshoff C: HHV-8 is associated with a plasmab-
lastic variant of Castleman disease that is linked to HHV-8-
positive plasmablastic lymphoma. Blood 2000, 95(4):1406-12.
7 . O k s e n h e n d l e r  E ,  D u a r t e  M ,  S o u l i e r  J ,  C a c o u b  P ,  W e l k e r  Y  a n d
Cadranel J: Multicentric Castleman's disease in HIV infection:
a clinical and pathological study of 20 patients. AIDS 1996,
10(1):61-7.
8. Zietz C, Bogner JR, Goebel FD and Lohrs U: An unusual cluster of
cases of Castleman's disease during highly active antiretrovi-
ral therapy for AIDS. N Engl J Med 1999, 340(24):1923-4.
9. Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC,
Hamoudi R, Daniel MT, Agbalika F, Boshoff C, Clauvel JP, Isaacson PG
and Meignin V: High incidence of Kaposi sarcoma-associated
herpesvirus-related non-Hodgkin lymphoma in patients with
HIV infection and multicentric Castleman disease. Blood 2002,
99(7):2331-6.
10. Case records of the Massachusetts General Hospital;
Weekly clinicopathological exercises. Case 39: A 66-year-old
man with demyelinative neuropathy and a retroperitoneal
mass. N Engl J Med 1990, 323:895-908.
11. Lachant NA, Sun NC, Leong LA, Oseas RS and Prince HE: Multicen-
tric angiofollicular lymph node hyperplasia (Castleman's dis-
ease) followed by Kaposi's sarcoma in two homosexual
males with the acquired immunodeficiency syndrome
(AIDS). Am J Clin Pathol 1985, 83:27-33.
12. Frizzera G, Peterson BA, Bayrd ED and Goldman A: A systemic
lymphoproliferative disorder with morphologic features of
Castleman's disease: clinical findings and clinicopathologic
correlations in 15 patients. J Clin Oncol 1985, 3(9):1202-16.
13. Kessler E: Multicentric giant lymph node hyperplasia. A
report of seven cases. Cancer 1985, 56(10):2446-51.
14. Munoz G, Geijo P, Moldenhauer F, Perez-Moro E, Razquin J and Piris
MA:  Plasmacellular Castleman's disease and POEMS
syndrome. Histopathology 1990, 17:172-4.
15. Oksenhendler E, Carcelain G and Aoki Y: High levels of human
herpesvirus 8 viral load, human interleukin-6, interleukin-10,
and C reactive protein correlate with exacerbation of multi-
centric Castleman Disease in HIV-infected patients.  Blood
2000, 96:2069.
16. Aaron L, Lidove O, Viard JP, Troisvallet D, Piketty C and Vittecoq D:
Castleman's disease in patients infected with HIV. Revue de
Medicine Interne 2002, 23(2):155-63.
17. Soulier J, Grollet L, Oksenhendler E, Miclea JM, Cacoub P, Baruchel
A, Brice P, Clauvel JP, d'Agay MF and Raphael M: Molecular analysis
of clonality in Castleman's disease. Blood 1995, 86(3):1131-8.
18. Gessain A, Sudaka A, Briere J, Fouchard N, Nicola MA and Rio B:
Kaposi sarcoma-associated herpes-like virus (human herpes-
virus type 8) DNA sequences in multicentric Castleman's
disease: is there any relevant association in non-human
immunodeficiency virus-infected patients?  Blood 1996,
87(1):414-6.
19. Du MQ, Liu H, Diss Ye H, Hamoudi RA, Cabecada J and Dong HT:
Kaposi sarcoma-associated herpesvirus infects monotypic
(Igm lambda) but polyclonal naive B cells in Castleman's dis-
ease and associated lymphoproliferative disorders.  Blood
2001, 97(7):2130-2136.
20. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D and Hayden
K: Brief report: alleviation of systemic manifestations of Cas-
tleman's disease by monoclonal anti-interleukin-6 antibody.
N Engl J Med 1994, 330(9):602-5.
21. Foussat A, Fior R, Girard T, Boue F, Wijdenes J and Galanaud P:
Involvement of human interleukin-6 in systemic manifesta-
tions of human herpesvirus type 8-associated multicentric
Castleman's disease. AIDS 1999, 13(1):150-2.
22. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T and Shirai
T: Improvement in Castleman's disease by humanized anti-
interleukin-6 receptor antibody therapy.  Blood 2000,
95(1):56-61.
23. Bardwick PA: Plasma cell dyscrasia with polyneuropathy,
organomegaly, endocrinopathy, M protein and skin changes.
The POEMS syndrome. Report on two cases and a review of
the literature. Medicine (Baltimore) 1980, 59:311-22.
24. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hattem D and
Bricet P: Kaposi's sarcoma-associated herpesvirus-like DNA
sequences in multicentric Castleman's disease.  Blood 1995,
86:1276-80.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/3/20/prepub